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Abstract
Coronavirus disease-19 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
represents one of the biggest challenges of 21st century, threatening public health around the globe. Increasing age and
presence of co-morbidities are reported risk factors for severe disease and mortality, along with autoimmune diseases (ADs)
and immunosuppressive treatments such as haematopoietic stem cell transplantation (HSCT), which are also associated with
adverse outcomes. We review the impact of the pandemic on specific groups of patients with neurological, rheumatological,
and gastroenterological indications, along with the challenges delivering HSCT in adult and pediatric populations. Moving
forward, we developed consensus-based guidelines and recommendations for best practice and quality of patient care in
order to support clinicians, scientists, and their multidisciplinary teams, as well as patients and their carers. These guidelines
aim to support national and international organizations related to autoimmune diseases and local clinical teams delivering
HSCT. Areas of unmet need and future research questions are also highlighted. The waves of the COVID-19 pandemic are
predicted to be followed by an “endemic” phase and therefore an ongoing risk within a “new normality”. These
recommendations reflect currently available evidence, coupled with expert opinion, and will be revised according to
necessary modifications in practice.
Introduction
Since the onset of the COVID-19 pandemic [1], various
reports detail its clinical manifestations and outcomes [2–6].
Delivery of HSCT requires maintenance of a complex
infrastructure, quality assured according to a range of
accreditation standards, and severely impacted during the
pandemic. Under normal circumstances, autologous and
allogeneic HSCT are performed in patients with severe ADs
after careful balance of benefits and risks, with
consideration of other non-transplant treatment options
[7–10]. The majority of such patients have chronic diseases,
which impact on quality of life and may shorten life
expectancy. Transplant regimens used in autologous HSCT
for ADs are generally more immunosuppressive than those
used for other indications [8], and patients often receive
immunomodulatory treatments prior and after HSCT.
Immunocompromised patients are at elevated risk of com-
plications from SARS-CoV-2 [11–17]. However, it remains
uncertain whether conventional immunosuppressive treat-
ments, glucocorticoid usage, and/or targeted-biologic dis-
ease modifying therapies (DMTs), are advantageous or
detrimental [18].
As a basis for our guidelines and recommendations, we
appraise the impact of the pandemic on patients with ADs,
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including non-HSCT treatments, along with the challenges
delivering HSCT during the initial waves of the COVID-19
pandemic. The current phase of the COVID-19 pandemic is
predicted to be followed by an “endemic” phase and
therefore an ongoing risk within a “new normality”. There
is therefore a need within the community for guidelines to
restart HSCT programs, whilst maintaining quality and
cautiously balancing risks and benefits against alternative
treatment options in each AD. These guidelines and
recommendations should be read in conjunction with gen-
eral and AD-specific guidelines from European Society for
Blood and Marrow Transplantation (EBMT) [19, 20]. They
aim to provide useful information and general principles for
national and international organizations and local clinical
teams across relevant AD specialties whilst complementing
guidelines and recommendations issued by other specialist
societies.
Methods
The recommendations (Tables 1–3) provided in this “living
document” reflect currently available evidence, COVID-
related guidelines regularly updated by EBMT [20], rele-
vant AD specialists and HSCT societies, policies and pro-
cedures produced by national authorities as well as local
and institutional policies, coupled with expert opinion from
an international multidisciplinary team (MDT). Evidence
was sourced from PubMed searches of original observations
and key reviews, including the previous EBMT guidelines
[7, 8, 19–21], and, where relevant, recent congress
presentations.
As per other EBMT guidelines and recommendations,
level of evidence for the efficacy of autologous HSCT in
ADs is systematically classified in three categories of
recommendations where HSCT should be considered (S/
CO/GNR—see Tables 2 and 3, and related footnotes)
[7, 21]. Strength of evidence supporting the assignment of a
particular category of recommendations is graded (levels I,
II, and III) based on consideration of health benefits, side
effects, and risks and balanced against the non-HSCT
options. Clinical priority, as determined by a relevant MDT
[22], has been classified as high, intermediate, or low, while
the COVID-19 Alert Level [23, 24] as very low, low,
moderate, high, or very high (see Tables 2 and 3, and
related footnotes).
Preliminary analysis of the impact of COVID-19
outbreak on HSCT programs for ADs
Across the EBMT registry, we investigated the impact of
the COVID-19 outbreak on transplant activity for ADs.
When the transplant activity for ADs during the pandemic
was compared with the corresponding time in 2019, a total
of 116 patients received an autologous HSCT between
March and December 2020, while 242 patients received
autologous HSCT the previous year in the same time frame
(Fig. 1). Compared to 2019, transplant activity for ADs
decreased by 52%. Nevertheless, indications remained
unchanged with multiple sclerosis (MS) and systemic
sclerosis (SSc) comprising 80% of transplants in ADs
reported to the EBMT in 2020, being HSCT an integral and
standard-of-care part of their treatment algorithms [21].
General recommendations for restarting HSCT
program in ADs
All AD patients considered for HSCT should be carefully
discussed at the local MDT meeting, with input from HSCT
and AD specialists and consideration of alternative treat-
ments [20]. If HSCT treatment is in the best interests of
patients, established treatment protocols for AD should be
followed, as per guidelines and evidence-based appraisals.
The ongoing learning curve will need to be extended into
longer-term modifications in clinical practice, with the
“restoration and recovery” or “reset” periods, during which
SARS-CoV-2 minimization can be completed, aiming to
overcome any further “resurges” and peaks. Consequently,
HSCT programs must be ready to rapidly adapt to this
change following the course of the pandemic and be able to
prioritize the process of delivering HSCT according to
clinical urgency [25], depending on virus, hospital, patient,
and HSCT-related factors (Table 1) [22, 25].
Nurses have a key role in explaining all the related pre-
cautions, including strict adherence to local policies relating
to visiting. Clear written information for patients and care-
givers should be provided, including measures to minimize
the risk of infection, and need for a dedicated caregiver,
having low risk of SARS-CoV-2 exposure, in the first
months after HSCT. Patients intending to travel abroad for
HSCT should consider carefully what arrangements are in
place to minimize the risk but also the provision of care post
discharge, especially if there are any potential travel
restrictions between the country of treatment and their home.
Since the COVID-19 situation varies substantially
between and within countries, we recognize that centers are
mandated to follow guidelines, policies, and procedures
decided by national authorities as well as local and insti-
tutional policies. Special consideration should be made
when the home base or country of the patient is different
from the HSCT center, where R numbers [26] and clinical
practice, including in relation to precautions, may differ. As
such arrangements will be individualized, there is a
recommendation that patients are systematically discussed
by and between MDTs at both sites, and, after the HSCT
procedure, there is a clear communication between the
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Table 1 Summary of general recommendations [19, 20, 22, 25, 91].
Key factors Recommendations Remarks
Virus-related
factors
• Surveillance of the local prevalence of virus in the community.
• Continuous updating of the reproduction number “R” [26], reflecting the
infectious potential of the disease.
• Tracing of the national and regional alert status.
• In the event of “resurges” and peaks or local outbreaks. it is likely that HSCT for AD
may again need to stop.
• Patients and families need to be counseled about the possibility of short notice
cancellation of their planned HSCT.




• Availability of IPC and PPE, COVID-19 vaccinationa for the staff.
• Testing and tracing of staff and patients (prior to mobilization and transplant).
• Ability to create COVID secure facilities with clear pathways to separate patients
from those that may have COVID.
• Adequate supportive services for the HSCT program including ICU beds.
• Suitable isolation facilities including single rooms with en suite facilities and for
patients that tested positive for SARS-CoV-2 rooms with negative pressure or
neutral pressure if this is not possible.
• Backlog of patients with hematological malignancies who will take priority.
• Discussing patients being considered for HSCT in appropriately constituted MDTs
meeting; established treatment protocols for AD should be followed; mobilization
with Cy provides additional disease control and requires consideration [7, 8].
• Visitors should generally not be admitted to transplant wards, except a single
caregiver with negative swab for children.
• In many countries HSCT follows established pathway for adult elective care but
patients may also need to access services urgently.
• Where possible and clinically appropriate there should be separated care pathways for
urgent and planned care, to eliminate the risk of nosocomial infection. Staff looking
after COVID-19-positive patients should not be involved in face-to-face care of
negative recipients.
• Most hospitals have developed physically separate defined zones and cohorted staffing
(reduced movement between COVID protected and non-protected areas).
• All patients have to be screened at hospital entrance with questionnaire and
temperature checks.
• Patients should be tested for COVID-19 prior to starting the collection procedure, and
before hospitalization for HSCT procedure, in order to protect the staff and other
patients within the apheresis unit and the transplant unit from the nosocomial spread,
and defer any transplant procedure in case of positivity for SARS-CoV-2 [20].
• It is important, however, that access to appropriate expertise is maintained and that
pathways are also compliant with JACIE measures.
• Risk minimization for other viral outbreaks is recommended, e.g., compliance of HCW
with seasonal influenza vaccination.
• Methods for communication between recipients, family members, and HCW such a
video calls should be supported.
Patient-related
factors
• Individual risk/benefit assessment and ability to give fully informed consent.
• Ability to self-isolate, PPE compliance, home infrastructure to allow self-isolation,
and agreement to comply with need to self-isolate.
• Financial factors pertinent to the need to work from home for the first months
following HSCT.
• Ability to attend clinical appointments without using public transportation.
• Post-transplant recovery and rehabilitation may be facilitated at home via
telehealth [22, 92, 93], enabling early discharge from hospital if the patient can be
safe and well-supported at home.
• Patients should be strongly advised to follow self-isolation and/or rigorous social
distancing during and after HSCT.
• The duration of this self-isolation should be carefully adapted on the COVID Alert
Levelb within the community and the status of post-transplant immune reconstitutionc,
ranging from a minimum of 3 months after AHSCT (Alert Level 2), 6 months (Alert
Level 3), 12 months (Alert Level 4), or until a full immune reconstitution (Alert
Level 5).
• Early influenza vaccination should be considered from 3 months after HSCT to
decrease risk of hospitalization [7, 20, 86, 89]. Likewise, routine post-transplant anti-
infective prophylaxis should be maintained as per guidance [7]. Moreover, optimizing
vitamin D status plays an essential role in the immune system and may potentially
have benefits in COVID-19 [94].
• Household contacts should receive COVID-19 vaccinationa.
HSCT-related
factors
• Consideration within the MDTs.
• Potential recipients should self-quarantine at home for 14 days and be swabbed
• Although in a general HSCT context consideration of a modified mobilization















































Key factors Recommendations Remarks
[20] (ideally within the 48 h and by molecular testing) prior to mobilization and
transplant [20, 22].
• Potential recipients should not be transferred to the transplant ward and should not
commence conditioning until a negative swab result has been reported.
• In case when potential recipient tests positive for SARS-CoV-2, any transplant
procedure (i.e., mobilization, collection, conditioning regimen) should be deferred
[20]. In patients with mild or asymptomatic SARS-CoV-2 infection, deferral of at
least 14 days after the first negative swab and symptoms clearance is required,
with an additional negative swab before the start of conditioning. Similar
minimum timeframes are advised from the time of last contact with a known
COVID-positive contact. Deferral of HSCT for at least 3 months is recommended
in patients with moderate–severe COVID-19.
in most AD protocols mobilization, the additional use of Cy provides additional
disease control and may prevent disease flares. Cryopreservation is recommended.
• Treatment in a clinical study, if available, should always be considered.
• Immunocompromised patients can have a prolonged SARS-CoV-2 shedding (weeks
or months), and recurrence of symptoms has been reported in a patient who became
severely immunocompromised.
• In the post-transplant period, patients with fever should be swabbed for SARS-CoV-
2 as part of the workup for investigation of infection [7, 22, 91, 95]. All swabs
should include testing for other respiratory viral pathogens [19]. Discussion of
treatment for SARS-CoV-2 infection is beyond the scope of these guidelines but
should follow the latest evidence available in local treatment guidelines and the
responsibility of an expert in treating SARS-CoV-2 infection, yet with involvement
of AD expert as the leading experts for the immunosuppressive therapy.
AHSCT autologous hematopoietic stem cell transplantation, ADs autoimmune diseases, IPC infection prevention and control, PPE personal protective equipment, COVID Coronavirus disease,
ICU intensive care unit, SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2, ATG anti-thymocyte globulin, GVHD graft-versus-host disease, HCW healthcare workers, Cy
cyclophosphamide, MDTs multidisciplinary teams.
aThe protective role of active immunization might be limited in case of extensive circulation of viral strain with certain mutations.
bCOVID-19 Alert Level [23, 24]—Level 1 (very low): COVID-19 is not known to be present; Level 2 (low): infection is present but the number of cases and transmission rate are low (R [26]
below 1, growth rate [26] below 0 and average weekly number of new cases of <20 per 100 000 population); Level 3 (moderate): infection is epidemic in the general population but transmission is
not high or rising exponentially (R [26] below 1, growth rate [26] below 0 and average weekly number of new cases of 20 or more per 100 000 population); Level 4 (high): infection is epidemic in
the general population; transmission is high or rising exponentially (R [26] above 1 and growth rate [26] above 0); Level 5 (very high): as Level 4 but with material risk of healthcare services
being overwhelmed.
cPost-transplant immune reconstitution [40, 96, 97] HSCT in ADs enables the regeneration of a new and non-disease-mediating immunity 40. The post-HSCT period is usually divided into the (1)
pre-engraftment period (day 0 to days 15–45), (2) immediate post-engraftment period (engraftment to day +100), and (3) late post-engraftment period (days +100 to +365). In general, the
neutrophil count recovers 2–3 weeks after HSCT. Recovery of B cells, natural killer (NK) cells, and CD8+ T cells is normally achieved in the first few weeks to 6 months, whereas CD4+ T-cell
reconstitution is usually slower, where replenishment in adults may require up to 2 years post-HSCT [98, 99]. During the pre-engraftment period, the risk of opportunistic infection varies
depending on the conditioning intensity (myeloablative or reduced intensity) [7, 40, 97]. In the post-engraftment period, the immune system is generally well-reconstituted and recovered in
autologous HSCT recipients. Moreover, the degree of immune recovery (eg serum IgG concentrations> 4 g/L and CD4+ count >200 cells/μL) is associated with clinical outcomes, thus











transplant center and the receiving site and their clinicians
for ongoing follow up and advice.
Considerations and recommendations for HSCT in
neurologic autoimmune diseases
Immune-mediated neurological disorders (IMNDs) affect
the central and the peripheral nervous systems resulting in a
range of diseases including MS, neuromyelitis optica
spectrum disorder (NMOSD), stiff person spectrum dis-
order, myasthenia gravis, chronic inflammatory demyeli-
nating polyradiculoneuropathy (CIDP), autoimmune
encephalopathies, and others [27].
The limited available evidence suggests that IMNDs and
their treatments affect the susceptibility to or the severity of
COVID-19. Patients with MS have increased risk of several
types of infections compared to the general population
particularly if they are on B-cell depleting therapies, such as
rituximab [28, 29]. An earlier study from Italy reported on
232 MS patients from 38 centers with confirmed or sus-
pected COVID-19 [30], did not show any significant asso-
ciation between previous DMT exposure and COVID-19
severity. Of those patients, 223 had mild, 4 had severe, and
6 had critical infection.
In a registry-based study of 347 patients with MS, age,
EDSS score, and obesity were found to be independent risk
factors for severe COVID-19, although no association was
found between DMTs exposure and COVID-19 severity
[31]. Another study suggested that the incidence of COVID-
19 in MS patients was not more than that of the general
Table 2 Summary of recommendations for autologous HSCT in neurologic autoimmune diseases in the time of COVID-19.
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Progressive MS with active
inflammatory component
CO/II 2 2 Registry
Progressive MS without active
inflammatory component
GNR/III N/A N/A N/A






Treatment-resistant CIDP CO/II 2 2 Registry












Rare IMNDs and treatment-resistant
systemic ADs
CO/II 2 2 Registry
Strength of evidence of clinical efficacy [7]—Grade I: evidence from at least one well-executed randomized trial, Grade II: evidence from at least
one well-designed clinical trial without randomization; cohort or case-controlled analytic studies, Grade III: evidence from opinions of respected
authorities based on clinical experience. Recommendations7: S standard of care, CO clinical option, GNR generally not recommended.
Clinical priority (as determined by a relevant multidisciplinary team) [22]—1: high, delaying the HSCT procedure presents a high risk of disease
progression, morbidity or mortality, 2: intermediate, there is a risk of disease progression or clinical complications if HSCT is delayed significantly,
3: low, the risk of disease progression or clinical complications if HSCT is significantly delayed is low.
COVID-19 Alert Level [23, 24]—Level 1 (very low): COVID-19 is not known to be present; Level 2 (low): infection is present but the number of
cases and transmission rate are low (R [26] below 1, growth rate [26] below 0 and average weekly number of new cases of less than 20 per 100 000
population); Level 3 (moderate): infection is epidemic in the general population but transmission is not high or rising exponentially (R [26] below
1, growth rate [26] below 0 and average weekly number of new cases of 20 or more per 100 000 population); Level 4 (high): infection is epidemic
in the general population; transmission is high or rising exponentially (R [26] above 1 and growth rate [26] above 0); Level 5 (very high): as Level
4 but with material risk of healthcare services being overwhelmed.
Setting [7]—prospective studies: randomized controlled trials (RCTs) and other clinical trials, including RAM-MS, STAR-MS, NET-MS,
COAST, BEAT-MS, or prospective non-interventional studies (NIS) including OMST [6]. Registry: reporting data to EBMT registry (or
equivalent international registry, e.g., CIBMTR).
HSCT autologous hematopoietic stem cell transplantation, MS multiple sclerosis, DMT disease modifying therapies, CIDP chronic inflammatory
demyelinating polyradiculoneuropathy, NMOSD neuromyelitis optica spectrum disorder, SPSD stiff person spectrum disorder, IMNDs immune-
mediated neurological disorders, ADs autoimmune diseases, CIBMTR Center for International Blood and Marrow Transplant Research, N/A not
applicable.
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population, but the risk of hospitalization in these patients
was higher than estimated for the disease [32]. The pre-
valence and impact of COVID-19 across Europe were
assessed in the 399 patients with MS taking part in the
RADAR-CNS programme [33]; of those 21.8% reported
major symptoms suggestive of COVID-19, mainly asso-
ciated to alemtuzumab and cladribine treatments. In the MS
Global Data Sharing Initiative [34], clinician-reported data
from 21 countries on 1540 patients in which 776 (50.4%)
had confirmed COVID-19, and confirmed that older age,
progressive MS, and higher EDSS scores were associated
with higher frequencies of severe outcomes. Anti-CD20
DMTs, ocrelizumab, and rituximab were positively asso-
ciated with hospital and ICU admission and the need for
artificial ventilation compared to all other DMTs.
Therefore, patients with MS seem to be affected by the
same risk factors as the general population, high EDSS
scores appear to be an MS-specific risk factor and the
majority of DMT treatment does not seem to be associated
with a particularly poor prognosis.
Data related to other IMNDs are limited. CARE-MG
registry reported worsening of myasthenic control requiring
rescue therapy in the setting of COVID-19 in 36 of 91
patients. Complete recovery or discharge to home was
reported in 39 (43%) patients whereas 22 (24%) patients
died due to COVID-19 [35]. The clinical course and out-
come of patients with COVID‐19 and NMOSD seem to be
variable [36–38] and also exacerbations of CIDP have been
reported [39].
The use of autologous HSCT in the treatment of IMNDs
is expanding and becoming increasingly evidence-based
[7, 40–42]. Recently, the first phase III randomized con-
trolled trial [41] in MS has demonstrated its efficacy in
patients with active relapsing remitting disease failing
standard DMTs. A number of phase II non-randomized
trials have also shown its safety and efficacy in treatment-
Table 3 Summary of
recommendations for autologous
HSCT in RMDs in the time of
COVID-19.






































Strength of evidence of clinical efficacy [21]—Grade I: evidence from at least one well-executed randomised
trial, Grade II: evidence from at least one well-designed clinical trial without randomization; cohort or case-
controlled analytic studies, Grade III: evidence from opinions of respected authorities based on clinical
experience. Recommendations [21]: S standard of care, CO clinical option, GNR generally not
recommended.
Clinical priority (as determined by a relevant multidisciplinary team) [22]—(1) high, delaying the HSCT
procedure presents a high risk of disease progression, morbidity, or mortality, (2) intermediate, there is risk
of disease progression or clinical complications if HSCT is delayed significantly, (3) low, the risk of disease
progression or clinical complications if HSCT is significantly delayed is low.
COVID-19 Alert Level [23, 24]—Level 1 (very low): COVID-19 is not known to be present; Level 2 (low):
infection is present but the number of cases and transmission rate are low (R [26] below 1, growth rate [26]
below 0 and average weekly number of new cases of <20 per 100 000 population); Level 3 (moderate):
infection is epidemic in the general population but transmission is not high or rising exponentially (R [26]
below 1, growth rate [26] below 0 and average weekly number of new cases of 20 or more per 100,000
population); Level 4 (high): infection is epidemic in the general population; transmission is high or rising
exponentially (R [26] above 1 and growth rate [26] above 0); Level 5 (very high): as Level 4 but with
material risk of healthcare services being overwhelmed.
Setting—prospective studies: randomized controlled trials (RCTs) and other clinical trials, or prospective
non-interventional studies (NIS). Registry: reporting data to EBMT registry (or equivalent international
registry, e.g., CIBMTR).
HSCT autologous hematopoietic stem cell transplantation, RMDs rheumatic and musculoskeletal diseases,
SSc systemic sclerosis, SLE systemic lupus erythematosus, RA rheumatoid arthritis, JIA juvenile idiopathic
arthritis, CIBMTR Center for International Blood and Marrow Transplant Research, N/A not applicable.
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resistant CIDP [43], SPS [44], and NMOSD [45], whilst
definitive data are less readily available [7, 27, 42, 46]. The
conditioning regimens usually employed in neurological
ADs range from high-dose cyclophosphamide and the
combination of BCNU, Etoposide, ARA-C and Melphalan,
both associated with serotherapy with either anti-thymocyte
globulin (ATG), rabbit or horse, or monoclonal antibodies
targeted to lymphocyte subsets, such as alemtuzumab or
rituximab [7]. The different intensity of the regimens results
in corresponding degrees of immunosuppression. In any
case, with any type of regimen, a patient would be con-
sidered at high risk in case of SARS-CoV-2 infection
[39, 47, 48].
The most appropriate choice of conditioning regimen
should be addressed for each individual patient, after a
careful assessment of diagnosis, disease stage, and overall
clinical condition at baseline. Therefore the use of this
treatment should be restricted to patients with a clear risk/
benefit ratio based on treatment-resistant disease entity,
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Fig. 1 Autologous hematopoietic stem cell transplant (HSCT) for
autoimmune diseases (ADs) 2019–2020, reflecting the impact of the
COVID-19 pandemic in Europe. a Numbers of autologous HSCT in
January to December 2020 are compared with the numbers in January
to December 2019; b 2019–2020 transplants are also represented
according to disease indication (MS: deep blue; SSc: light blue; CD:
green; other ADs: yellow). auto-HSCT autologous hematopoietic stem
cell transplantation, AD autoimmune disease, MS multiple sclerosis,
SSc systemic sclerosis, CD Crohn’s disease.
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efficacy in this particular disease, defined clinical priorities
[22], and local COVID-19 Alert Levels (Table 2) [23].
All treatment-related decisions should be made by MDTs
and patients should be treated within clinical trials if
available or as part of well-defined registry studies to allow
longitudinal collection of efficacy and safety data of the
various treatment options. Patients with severe co-
morbidities known to be associated with poor COVID-19
outcomes should not be considered for HSCT during the
pandemic.
Considerations and recommendations for HSCT in
rheumatic diseases
The COVID-19 pandemic has considerable impact on dif-
ferent aspects of the management of patients with rheumatic
and musculoskeletal diseases (RMDs). Chronic suppression
of immune functions, both with synthetic or biologic
DMTs, is the cornerstone of treatment in those indications
[49–53]. Alongside, autologous HSCT has emerged as an
established treatment option for some indications where
effective drug therapy is not available, even in the biolo-
gical era. Particularly, three randomized controlled trials
(ASSIST, ASTIS and SCOT) have demonstrated the
superiority of HSCT compared to monthly IV bolus of
cyclophosphamide in patients with early rapidly progressive
SSc in terms of event-free and overall survival, improve-
ment of skin fibrosis, and evidence for benefits on pul-
monary function [54–56]. SSc is now considered a standard
indication for autologous HSCT [21, 57]. Other diseases in
which the use of HSCT is supported by evidence from non-
randomized controlled trials and is regarded as treatment
option include systemic lupus erythematosus (SLE), vas-
culitides, polymyositis/dermatomyositis, and both rheuma-
toid and juvenile idiopathic arthritis [21].
Chronic use of DMTs may be associated with an
increased risk of infection-related morbidity and mortality
in RMDs [58, 59]. However, despite this notion, accumu-
lating data from larger case series, national and international
registries suggest that patients with RMDs neither have an
increased risk of developing SARS-CoV-2 infection nor do
they have a worse prognosis compared to the general
population [60–63]. Only RMD patients on high-dose cor-
ticosteroids, but not methotrexate and biologic DMTs, non-
steroidal anti-inflammatory drugs and antimalarial drugs
had a higher risk of SARS-CoV-2 infection or hospitaliza-
tion [60–62, 64, 65]. However, recent data from the French
RMD COVID-19 cohort including 694 adults indicated for
the first time an increased risk for severe infection in
patients receiving mycophenolate mofetil or rituximab [65].
Conversely, RMD patients on a background tumor necrosis
factor (TNF) inhibitor had an adjusted 60% reduction in risk
of hospitalization [62], and recently the FDA authorized the
emergency use of baricitinib in certain hospitalized patients
with COVID-19. Overall, risk factors for more severe
COVID-19 in RMD patients include older age and
comorbid conditions [65]. The only rheumatic disease
diagnosis with odds of hospitalization significantly different
from other RMDs seems to be SLE. Data from the Global
Rheumatology Alliance (GRA) Registry indicated that
lupus patients were at 80% increased risk of hospitalization
[62]. Patients with SSc are largely underrepresented in
international COVID-19 registries and their risk during
COVID-19 pandemic is evaluated incompletely. Never-
theless, first single-center studies and personal observations
indicated that incidence of confirmed SARS-CoV-2 infec-
tions was low and severe complications, including death,
were rare. Only one death and 11 infections related to
COVID-19 have been reported among 526 Italian SSc
patients [66]. Overall, 390 (10.5%) died out of 3729 RMD
patients included in the GRA physician COVID-19 registry
[67]. Provisional recommendations for the management of
RMD patients were published based on expert consensus
from international task forces of the EULAR [68] and ACR
[69]. Both recommendations strongly suggest continuing
the DMTs treatment in RMD patients who do not have
suspected or confirmed COVID-19. In addition, manage-
ment of RMD patients following SARS-CoV-2 exposure
and documented infection, and the use of immunosuppres-
sive drugs, should be multidisciplinary, discouraging the
off-label use of DMTs outside the context of clinical
trials [68].
The use of HSCT in RMDs must be carefully weighed
against the risk of the procedure, should be based on the
strengths of evidence per indication and ideally performed
as part of a clinical study. Particularly, access to intensive
care medicine and resources for appropriate screening pro-
cedures, including the recommended cardiopulmonary
screening assessments for SSc patients should be available
[63]. Appropriate candidates for autologous HSCT during
COVID-19 pandemic should therefore be those with high
clinical priority, reflected by life-threatening and otherwise
refractory courses of the disease, i.e., unresponsiveness or
lack of tolerability to standard or alternative DMTs thera-
pies, in which delaying the HSCT procedure may be asso-
ciated with a high risk of disease progression, morbidity, or
mortality (Table 3).
In summary, continuation with autologous HSCT for
RMD patients during COVID-19 pandemic can be recom-
mended, presupposing a risk adjustment according to local
SARS-CoV-2 infection rates and medical resources,
strengths of evidence of HSCT per indication, lack of
alternative therapies and adoption of a prioritization pro-
cess, delivering HSCT based on clinical urgency.
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Considerations and recommendations for
gastrointestinal diseases
In gastroenterology, the main area application of autologous
HSCT has been in inflammatory bowel diseases (IBDs),
particularly Crohn’s disease (CD) [9, 10]. Although the
COVID-19 pandemic has led to substantial concerns for
patients with IBDs, as a high proportion of them receive
immunosuppressive therapies [70], similar COVID-19 rates
and no increased mortality have been reported as compared
to the general population [71–73]. Corticosteroids may pose
significant risk to IBD patients with COVID-19 [72]. In
addition, recent results demonstrated that thiopurine treat-
ment, either as monotherapy or in combination with TNF
inhibitors, was associated with increased risk of severe
COVID-19 [74, 75]. Anti-TNF therapy, anti-integrins, and
anti-IL12/23 have not been associated with increased mor-
tality [71, 73].
Recommendations in the management of IBD suggest
that medical treatments should be re-evaluated in SARS-
CoV-2-positive patients and corticosteroid therapy should
be re-evaluated regardless of symptoms. A goal should be
to treat active disease and maintain remission, while
adopting the same protective measures as the general
population. In addition, nonurgent surgeries and endoscopic
procedures should be postponed [76]. The use of autologous
HSCT should be restricted to patients with a clear risk/
benefit ratio, according to strengths of evidence of HSCT
per indication, clinical priorities [22], and local COVID-19
Alert Levels (Table 4) [23].
Considerations and recommendations for pediatric
population
Only limited data are available on risks of HSCTs in
pediatric ADs [76, 77] during the COVID-19 outbreak [30].
There was no significant association between previous
DMTs and COVID-19 severity in children [77]. Therefore,
children post-HSCT for ADs usually have a story of
intensive immunosuppression and are at potential risk dur-
ing the COVID-19 outbreak [13]. A rapid global response
for children with cancer was published [78]. Feasibility of
HSCT for pediatric ADs during the COVID-19 outbreak
was demonstrated, provided there is the availability of
hospital resources. Therefore, during the pandemic out-
break, the indication for HSCT in children with ADs must
be restricted to patients with a clear risk/benefit ratio [78]. In
children, it could be severe “malignant” forms of neurolo-
gical ADs, severe progressive systemic diseases, CD, and
immune cytopenias.
Considering the better outcomes of HSCT in children
during the COVID-19 outbreak, a less restrictive approach
could be applied [79]. As patients with pediatric ADs are
mostly transplanted in the same departments as patients
with malignancies, priority must be given to these children
followed by patients with severe ADs [78]. Centers must be
very careful using immunotherapy such as ATG as well as
monoclonal antibodies [80]. Preferably, only one parent or
guardian, identified as the primary caregiver, and with a
recent negative swab for SARS-CoV-2, may be present in
the room with a pediatric patient, requesting a visitor
exception to the local care team.
Special recommendations for vaccinations
The response to the pandemic includes efforts to develop
safe and effective vaccines [81] with an unprecedented
urgency and large-scale investment of human and financial
resources [82].
All the main arms of the immune response are involved
in the generation of protective immunity to SARS-CoV-2:
innate immune responses as well as adaptive immunity,
including humoral and T-cell responses. SARS-CoV-2 has
the ability to suppress innate immune responses [81].
Antibody responses to the Coronavirus spike (S) protein
develop during COVID-19 infection in the majority of
subjects [83]. Emerging evidence indicates that T-cell
mediated immunity may be critically important against
COVID-19 [81, 84, 85]. Collectively, these data suggest
that individuals with compromised innate or adaptive
immunity may not only be at risk of more severe COVID-
19 disease but also at higher risk of lacking protective
immunity from infection or vaccination.
The guidelines of the 2017 European Conference on
Infections in Leukaemia provide general recommendations
for vaccination in HSCT recipients [86]. Recently, EBMT
has provided specific COVID-19 vaccine recommendations
[20]. The vaccines against COVID-19 currently approved
for use in EU, following review by EMA, can be grouped in
two platforms: recombinant replication-defective viral-vec-
tored vaccines and mRNA-based vaccines [20, 81]. No
evidence is published to inform us on the safety and efficacy
of any COVID-19 vaccine in HSCT recipients. Based on
inferences from other current evidence [20, 87, 88], we
suggest that live-attenuated COVID-19 vaccines or vectored
by live-attenuated viruses should be contraindicated in
HSCT recipients. For all other COVID-19 vaccine types,
we suggest that vaccination could be considered from
3 months after HSCT. Follow-up after vaccination is
therefore important. Continued precautions should be taken
based on the pandemic situation in the society [20, 89].
Individuals vaccinated before HSCT will almost certainly
lose protective immunity after HSCT and may require
revaccination. Clinical trials in HSCT patients are needed to
establish the safety and immune response of vaccines
against COVID-19.
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Data reporting
Routine data reporting should continue into the EBMT
registry, and, alongside, we strongly encourage center par-
ticipation in the ongoing EBMT-wide prospective survey on
the impact of COVID-19 in HSCT recipients [19].
Clinical trials
With respect to clinical trials, special consideration should
be made by trial management groups, oversight committees,
sponsors, and local principal investigators in the best
interests of patients in relation to the trial protocol and
recruitment during the pandemic [90]. Even so, clinical
trials provide a means of actively monitoring the impact of
the COVID-19 pandemic on outcomes.
Quality and accreditation
In EBMT, quality in HSCT and cellular therapy is assured
through JACIE accreditation, which has been central to
EBMT recommendations for HSCT in ADs [8]. Elsewhere,
equivalent quality assurance is provided by FACT, based on
harmonized FACT—JACIE standards. Therefore, we
recommend that HSCT procedure should only be carried
out in experienced centers with an active accreditation by
JACIE or FACT [7].
As the situation may change over time, the current
statements should be reviewed at regular intervals and read
in conjunction with general EBMT guidelines [20] on the
COVID-19 pandemic, which are continually updated [20],
along with local and national guidance.
Conclusions
Although current evidence suggests that HSCT is a valid
treatment option in the management of selected patients
with ADs, its intense immunosuppression could expose to
increased risks during the current COVID-19 pandemic
[13, 47, 48]. Therefore the use of autologous HSCT
during the pandemic should be restricted to AD patients
with a clear risk/benefit ratio based on disease entity, level
of evidence for HSCT efficacy in this setting, defined
clinical priorities [22], and local COVID-19 Alert Levels
(Tables 2–4) [23]. All patients being considered for HSCT
should be discussed in appropriately constituted MDT
meetings (including transplant and disease specialists) with
individual assessment of risks and benefits of HSCT as
best as possible and considering the current and predicted
Table 4 Summary of
recommendations for autologous
HSCT in IBDs in the time of
COVID-19.




















Strength of evidence of clinical efficacy [21]—Grade I: evidence from at least one well-executed randomised
trial, Grade II: evidence from at least one well-designed clinical trial without randomization; cohort or case-
controlled analytic studies, Grade III: evidence from opinions of respected authorities based on clinical
experience. Recommendations [21]: S standard of care, CO Clinical option, GNR generally not
recommended.
Clinical priority (as determined by a relevant multidisciplinary team) [22]— (1) high, delaying the HSCT
procedure presents a high risk of disease progression, morbidity or mortality, (2) intermediate, there is risk of
disease progression or clinical complications if HSCT is delayed significantly, (3) low, the risk of disease
progression or clinical complications if HSCT is significantly delayed is low.
COVID-19 Alert Level [23, 24]—Level 1 (very low): COVID-19 is not known to be present; Level 2 (low):
infection is present but the number of cases and transmission rate are low (R [26] below 1, growth rate [26]
below 0 and average weekly number of new cases of <20 per 100,000 population); Level 3 (moderate):
infection is epidemic in the general population but transmission is not high or rising exponentially (R [26]
below 1, growth rate [26] below 0 and average weekly number of new cases of 20 or more per 100,000
population); Level 4 (high): infection is epidemic in the general population; transmission is high or rising
exponentially (R [26] above 1 and growth rate [26] above 0); Level 5 (very high): as Level 4 but with
material risk of healthcare services being overwhelmed.
Setting—prospective studies: randomized controlled trials (RCTs) and other clinical trials, or prospective
non-interventional studies (NIS). Registry: reporting data to EBMT registry (or equivalent international
registry, e.g., CIBMTR).
HSCT autologous hematopoietic stem cell transplantation, IBD inflammatory bowel diseases, RCD refractory
celiac disease, CIBMTR Center for International Blood and Marrow Transplant Research, N/A not applicable.
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geographical variations in the pandemic related to transplant
center, referral center, and home locality of the patient
(which may be different). HSCT programs must be ready
to rapidly adapt to change following the course of the
pandemic. Updates of this COVID-19-specific guidance
will be incorporated within updates to recommendations
from EBMT for specific ADs.
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